SYMBICORT for your asthma patients 6 to <12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

SYMBICORT

for pediatric asthma patients as young as 6 years1

FOR PEDIATRIC PATIENTS 6 TO LESS THAN 12 YEARS OF AGE1
80/4.5 mcg 2 inhalations BID

The only ICS/LABA in a pMDI with efficacy data approved for pediatric patients as young as 6 years

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

SYMBICORT for your asthma patients 6 to <12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

SYMBICORT-NOW APPROVED

for pediatric asthma patients as young as 6 years1

The only ICS/LABA in a pMDI with efficacy data approved for pediatric patients as young as 6 years

FOR PEDIATRIC PATIENTS 6 TO LESS THAN 12 YEARS OF AGE1
80/4.5 mcg 2 inhalations BID

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

  • Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. SYMBICORT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Beta-adrenergic agonist medications may produce hypokalemia and hyperglycemia in some patients. As with other inhaled medications, paradoxical bronchospasm may occur with SYMBICORT. Use with caution in patients with diabetes mellitus
  • Do not use any additional long-acting beta2-agonists with SYMBICORT for any reason
  • The maximum daily recommended dose is 640/18 mcg budesonide/formoterol (given as two inhalations of SYMBICORT 160/4.5 twice daily) for patients 12 years and older. Do not use more than twice daily or use a higher number of inhalations (more than two inhalations twice daily) of the prescribed strength of SYMBICORT as this will result in a daily dose of formoterol in excess of the dose determined to be safe
  • Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids
  • Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (for example, discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an ICS
  • SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

pMDI=Pressurized metered-dose inhaler.

*Subject to eligibility rules; restrictions apply.

Improvement in lung function was demonstrated in 12-week efficacy and safety study.1

Administered in the morning and the evening.